Mon, Jan 26, 2015, 5:53 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • swissmilkcow_10 swissmilkcow_10 Mar 11, 2014 4:06 AM Flag

    ! New reports out - CLDX PT $40 !

    Wedbush
    Reiterate OUTPERFORM rating and our $40 price target.
    CLDX has built a small commercial team to begin efforts to support product
    launches, including global market opportunity assessment, reimbursement
    and payor landscape evaluation, target product profiles, clinical trial support,
    and brand name development.
    --
    Guggenheim
    CLDX - BUY - 4Q13 Results; Key CDX-1127 Ph.I Results on NT Horizon; Increasing
    PT to $37
    --
    Roth
    CLDX: 2013 Results; Trial Initiations and Data
    in 2014; Reiterate Focus Pick
    We reiterate our Focus Pick and $40 price target. We believe CLDX is
    solidifying its position as a premier cancer immunotherapy company with a
    broad pipeline and partnering potential.
    --
    Leerink
    Our price target on CLDX remains $45
    DDD Trial Terminated, But IO Program Expands
    Efficacy signals from CDX-1401 follow-up data discussed by
    management look quite intriguing to us, especially in light of literature
    reports of enhanced efficacy of Yervoy in NY-ESO-1 seropositive
    patients. Therefore CDX-1401 potentially could be a more important IO
    asset than previously thought.
    --
    Brean Capital
    4Q13 A Non-Event – CDX-1135 Termination Does Not
    Justify Today’s Selloff
    Buy
    PT: $35.00

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • lots good those reports did. Those #$%$ analyst an there upgrades are a joke.

    • swissmilkcow_10 , thanks for posting all of these "BUY" recommendations : Wedbush, Guggenheim, Roth,Leerink, and Brean Capital.. Since their recommendations CLDX stock has dropped more than 50%..
      Do you have any new list of "sell" recommendations ??

    • Wedbush
      Rindopepimut (CDX-110): CLDX expects to complete enrollment of the Phase III
      ACT IV study in the frontline EGFRvIII-positive glioblastoma (GBM) setting and the
      Phase II ReACT study in the recurrent GBM setting in mid-2014 and late 2014,
      respectively. Data from the Phase II ReACT study is expected at the Society for
      NeuroOncology meeting (November 13-16). CLDX estimates that 50% of the
      events (first interim analysis trigger) will be reached at around YE14/early 2015,
      75% of events (second interim analysis trigger) will be reached approximately
      6 months later, with the study mature for final analysis in 2015/early 2016. The
      company notes that it would have a better idea of the timing in H214.
      Glembatumumab vedotin (CDX-011): CLDX plans to initiate Phase II studies of
      CDX-011 in the metastatic melanoma and the squamous cell lung cancer settings
      in 2014 and continues enrollment of patients for the METRIC study of CDX-011 in
      the triple negative breast cancer setting (see next page). The METRIC study is
      80% powered to detect a 2.25-month improvement in PFS and a 30%
      (glembatumumab) versus 15% (capecitabine) response rate.
      Varlilumab (CDX-1127): Initial data from the Phase 1 solid tumor expansion
      cohorts and hematologic dose escalation cohorts are anticipated at the American
      Society for Clinical Oncology Meeting (May 30-June 3), and initiations of additional
      expansion in lymphocytic malignancies (including T-cell lymphomas). CLDX also
      plans to initiate two Phase 1/2 studies of varlilumab in combination with checkpoint
      inhibitors in the metastatic melanoma setting in 2014 (see next page).
      CLDX has built a small commercial team to begin efforts to support product
      launches, including global market opportunity assessment, reimbursement
      and payor landscape evaluation, target product profiles, clinical trial support,
      and brand name development.
      Reiterate OUTPERFORM rating and our $40 price target.

      • 1 Reply to swissmilkcow_10
      • Leerink
        •Efficacy signals from CDX-1401 follow-up data discussed by
        management look quite intriguing to us, especially in light of literature
        reports of enhanced efficacy of Yervoy in NY-ESO-1 seropositive
        patients. Therefore CDX-1401 potentially could be a more important IO
        asset than previously thought. Our price target on CLDX remains $45.
        • Looking ahead to the remainder of 2014, aside from multiple
        initiations in clinical programs, main catalysts for CLDX in 2014 could
        include data update for varli Phase I expansion cohorts in solid tumor
        and hematologic malignancies at ASCO, as well as rindopepimut ReACT
        Phase II data in glioblastoma (GBM) at SNO (Nov. 13-16, 2014). An early
        initiation of a combination study for varli with a PD-1 or PDL1 blocker
        would be positive, in our view, although management will have to weigh
        the pros and cons of starting the combination early vs. retaining greater
        downstream economic rights.
        • CDX-1401 could be a more relevant asset than previously thought.
        Long-term follow-up data with CDX-1401, a fusion protein that directs
        the NY-ESO-1 antigen to dendritic cells, showed some preliminary
        but intriguing signals suggesting that predisposition of CDX-1401
        may potentiate response to immune checkpoint inhibitors. Four out
        of six patients who received subsequent Yervoy therapy 3-4 months
        after CDX-1401 treatment showed some tumor responses (2 RECIST
        partial responses [PR], 1 complete response, 1 immune-related PR).
        Additionally, two non-small cell lung cancer (NSCLC) patients who were
        PDL1-negative received a PD1/PDL1 inhibitor (which management has
        information on but could not disclose) within two months of discontinuing
        CDX-1401 and also showed partial responses. These observations
        were consistent with other studies including 1) NY-ESO-1 seropositive
        melanoma patients have greater likelihood of experiencing clinical
        benefit 23 weeks after ipilimumab treatment (Yuan et al., PNAS, 2011,
        108:16723), 2) in NY-ESO-1 seropositive melanoma...

    • if these 5 recommendations have any credential, should CLDX stock up today ?
      Unfortunately, stock price seems to suggest that wholesale investors are dumping their shares while retail investors are holding in hope that 12 months from now, CLDX stock will move higher from here...
      Why should I believe any of these recs if stock price shows otherwise ?

    • temporal@prodigy.net temporal Mar 11, 2014 12:13 PM Flag

      Thanks swiss! Great post

      Sentiment: Strong Buy

    • "Therefore CDX-1401 potentially could be a more important IO
      asset than previously thought. "

      1127: best in class!

      Sentiment: Strong Buy

    • Thanks for posting.
      Great volume today in support of pps increase.
      CLDX tested the base, now going back to $30!

      Sentiment: Strong Buy

    • yeah. Anyone taking a critical look at the value proposition woudl have to come to similar conclusion (i.e. upside still remains in Celldex market cap).

      Sentiment: Strong Buy

    • Bump, bump, bump

    • Good morning Swiss, DAMM its been a long time since I have seen you post! Was these reports new ? I have not seen them. Funny how they came out at the low, but nice to see. Temporal good to see you pop up, I know you have been here just as long as myself, maybe longer. I may start posting again. I have been here since the $Avant days and have seen many changes for the good. Celldex seems to be real close to being a commercial biotech.. Been waiting a long time for this. I see Celldex moving back to the 52 week high in the next few months. jmho

 
CLDX
23.24+0.49(+2.15%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.